Despite its proven activity as third-line treatment in gastrointestinal stromal tumors (GIST), regorafenib can present a poor tolerability profile which often leads to treatment modifications and transient or permanent discontinuation; thus, in clinical practice physicians usually adopt various dosing and interval schedules to counteract regorafenib-related adverse events and avoid treatment interruption. The aim of this real-world study was to investigate the efficacy and safety of personalized schedules of regorafenib in patients with metastatic GIST, in comparison with the standard schedule (160 mg daily, 3-weeks-on, 1-week-off).

Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study

Merlini, A;D'Ambrosio, L;Tolomeo, F;
2021-01-01

Abstract

Despite its proven activity as third-line treatment in gastrointestinal stromal tumors (GIST), regorafenib can present a poor tolerability profile which often leads to treatment modifications and transient or permanent discontinuation; thus, in clinical practice physicians usually adopt various dosing and interval schedules to counteract regorafenib-related adverse events and avoid treatment interruption. The aim of this real-world study was to investigate the efficacy and safety of personalized schedules of regorafenib in patients with metastatic GIST, in comparison with the standard schedule (160 mg daily, 3-weeks-on, 1-week-off).
2021
6
4
100222
100227
GIST; personalized treatment; quality of life; regorafenib; toxicity; Humans; Phenylurea Compounds; Pyridines; Retrospective Studies; Gastrointestinal Stromal Tumors
Nannini, M; Rizzo, A; Nigro, M C; Vincenzi, B; Mazzocca, A; Grignani, G; Merlini, A; D'Ambrosio, L; Tolomeo, F; Badalamenti, G; Incorvaia, L; Bonasera...espandi
File in questo prodotto:
File Dimensione Formato  
2021 - ESMO Open - Regorafenib personalized schedule.pdf

Accesso aperto

Descrizione: Full text
Tipo di file: PDF EDITORIALE
Dimensione 395.2 kB
Formato Adobe PDF
395.2 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1869107
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 8
social impact